Editorial

Split Viewer

Blood Res 2014; 49(2):

Published online June 25, 2014

https://doi.org/10.5045/br.2014.49.2.75

© The Korean Society of Hematology

How old is old: the beginning of a new era for therapeutic challenges for elderly patients with AML

Hee-Je Kim, M.D. Ph.D.

Division of Hematology, Department of Internal Medicine, Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

  1. National Cancer Institute. The SEER Program. Bethesda, MD: National Institutes of Health; [Accessed June 17, 2014]. , at http://seer.cancer.gov/about/
  2. Oran, B, Weisdorf, DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica, 2012;97;1916-1924.
    Pubmed
  3. Ustun, C, Lazarus, HM, Weisdorf, D. To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant, 2013;48;1497-1505.
    Pubmed
  4. Juliusson, G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk, 2011;11;S54-S59.
    Pubmed
  5. Oshima, K, Takahashi, W, Asano-Mori, Y, et al. Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS). Ann Hematol, 2012;91;1533-1539.
    Pubmed
  6. Baz, R, Rodriguez, C, Fu, AZ, et al. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer, 2007;110;1752-1759.
    Pubmed
  7. Yi, HG, Lee, MH, Kim, CS, et al. Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis. Blood Res, 2014;49;95-99.
  8. Al-Ali, HK, Jaekel, N, Niederwieser, D. The role of hypomethylating agents in the treatment of elderly patients with AML. J Geriatr Oncol, 2014;5;89-105.
    Pubmed
  9. Eom, KS, Kim, HJ, Cho, BS, et al. Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia. Leuk Lymphoma, 2011;52;2321-2328.
    Pubmed
  10. Yoon, JH, Cho, BS, Kim, HJ, et al. Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status. Am J Hematol, 2013;88;1074-1081.
    Pubmed

Article

Editorial

Blood Res 2014; 49(2): 75-76

Published online June 25, 2014 https://doi.org/10.5045/br.2014.49.2.75

Copyright © The Korean Society of Hematology.

How old is old: the beginning of a new era for therapeutic challenges for elderly patients with AML

Hee-Je Kim, M.D. Ph.D.

Division of Hematology, Department of Internal Medicine, Cancer Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    References

    1. National Cancer Institute. The SEER Program. Bethesda, MD: National Institutes of Health; [Accessed June 17, 2014]. , at http://seer.cancer.gov/about/
    2. Oran, B, Weisdorf, DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica, 2012;97;1916-1924.
      Pubmed
    3. Ustun, C, Lazarus, HM, Weisdorf, D. To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant, 2013;48;1497-1505.
      Pubmed
    4. Juliusson, G. Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. Clin Lymphoma Myeloma Leuk, 2011;11;S54-S59.
      Pubmed
    5. Oshima, K, Takahashi, W, Asano-Mori, Y, et al. Intensive chemotherapy for elderly patients with acute myelogeneous leukemia: a propensity score analysis by the Japan Hematology and Oncology Clinical Study Group (J-HOCS). Ann Hematol, 2012;91;1533-1539.
      Pubmed
    6. Baz, R, Rodriguez, C, Fu, AZ, et al. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia. Cancer, 2007;110;1752-1759.
      Pubmed
    7. Yi, HG, Lee, MH, Kim, CS, et al. Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis. Blood Res, 2014;49;95-99.
    8. Al-Ali, HK, Jaekel, N, Niederwieser, D. The role of hypomethylating agents in the treatment of elderly patients with AML. J Geriatr Oncol, 2014;5;89-105.
      Pubmed
    9. Eom, KS, Kim, HJ, Cho, BS, et al. Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia. Leuk Lymphoma, 2011;52;2321-2328.
      Pubmed
    10. Yoon, JH, Cho, BS, Kim, HJ, et al. Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status. Am J Hematol, 2013;88;1074-1081.
      Pubmed
    Blood Res
    Volume 59 2024

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download